Everest Medicines licenses exclusive rights to commercialise DMX-200 for the treatment of Focal Segmental Glomerulosclerosis (FSGS) in Greater China, South Korea and Southeast Asia500,000-1 million ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results